Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Resistant hypertension. Intervention: Mineralocorticoid receptor blockade.

Bertram Pitt; George L. Bakris

doi:10.1093/eurheartj/ehad299

May 24, 2023European Heart Journal

Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade

View at Publisher

Ask AI

Bookmark

Share

Key result

Mineralocorticoid receptor blockade provides cardiorenal protection in patients with resistant hypertension.

Why the study?

Does mineralocorticoid receptor blockade improve cardiorenal protection in patients with resistant hypertension?

Key Points

To review the pathophysiological mechanisms and clinical therapeutic benefits of mineralocorticoid receptor blockade in resistant hypertension.
Synthesized mechanistic and clinical trial evidence regarding mineralocorticoid receptor antagonist therapy.
Evaluated cardiovascular and renal endpoints associated with targeted aldosterone pathway inhibition.
Mineralocorticoid receptor blockade significantly mitigates persistent blood pressure elevations in resistant hypertension.
Inhibition of mineralocorticoid signaling reduces vascular inflammation, endothelial dysfunction, and cardiorenal fibrosis.

Structured PICO

Does mineralocorticoid receptor blockade improve cardiorenal protection in patients with resistant hypertension?

P

Population

Patients with resistant hypertension

I

Intervention

Mineralocorticoid receptor blockade

O

Outcome

Cardiorenal protection

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This article discusses the role of mineralocorticoid receptor blockade for cardiorenal protection in resistant hypertension.

Abstract

Journal Article Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade Get access Bertram Pitt, Bertram Pitt Department of Medicine, University of Michigan Medicine, Ann Arbor, MI, USA https://orcid.org/0000-0001-5880-275X Search for other works by this author on: Oxford Academic PubMed Google Scholar George L Bakris George L Bakris Department of Medicine, University of Chicago Medicine, 5841 S. Maryland Ave. MC 1027, Chicago, IL 60637, USA Corresponding author. Tel: 1-773-702-7936, Fax: 1-773-834-2735, E-mail: gbakris@uchicago.edu https://orcid.org/0000-0003-1183-1267 Search for other works by this author on: Oxford Academic PubMed Google Scholar European Heart Journal, ehad299, https://doi.org/10.1093/eurheartj/ehad299 Published: 24 May 2023

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Pitt et al. (2023) conducted an editorial in Resistant hypertension. Mineralocorticoid receptor blockade was evaluated. Mineralocorticoid receptor blockade provides cardiorenal protection in patients with resistant hypertension.

synapsesocial.com/papers/6a0ebc3437aeb0126447a612 https://doi.org/10.1093/eurheartj/ehad299

View at Publisher

Ask AI

Bookmark

Share

Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Resistant hypertension: cardiorenal protection with mineralocorticoid receptor blockade

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading